Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy

Abstract Hepatocyte growth factor and its receptor cMet activate biological pathways necessary for repair and regeneration following kidney injury. Here, we evaluated the clinical role of urinary cMet as a prognostic biomarker in diabetic nephropathy (DN). A total of 218 patients with DN were enroll...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Chul Kim, Jung Nam An, Jin Hyuk Kim, Young-Wook Choi, Sohee Oh, Sang Ho Kwon, Mi-Young Lee, Junghun Lee, Jae-Gyun Jeong, Chun Soo Lim, Yon Su Kim, Seung Hee Yang, Jung Pyo Lee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/00399e8fbf4e4a6fbd44b1b1795bdc1f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:00399e8fbf4e4a6fbd44b1b1795bdc1f
record_format	dspace
spelling	oai:doaj.org-article:00399e8fbf4e4a6fbd44b1b1795bdc1f2021-12-02T15:08:44ZSoluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy10.1038/s41598-018-31121-12045-2322https://doaj.org/article/00399e8fbf4e4a6fbd44b1b1795bdc1f2018-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-31121-1https://doaj.org/toc/2045-2322Abstract Hepatocyte growth factor and its receptor cMet activate biological pathways necessary for repair and regeneration following kidney injury. Here, we evaluated the clinical role of urinary cMet as a prognostic biomarker in diabetic nephropathy (DN). A total of 218 patients with DN were enrolled in this study. We examined the association of urine cMet levels and long-term outcomes in patients with DN. The levels of urinary cMet were higher in patients with decreased renal function than in patients with relatively preserved renal function (5.25 ± 9.62 ng/ml versus 1.86 ± 4.77 ng/ml, P = 0.001). A fully adjusted model revealed that a urinary cMet cutoff of 2.9 ng/mL was associated with a hazard ratio for end-stage renal disease of 2.33 (95% confidence interval 1.19–4.57, P = 0.014). The addition of urinary cMet to serum creatinine and proteinuria provided the highest net reclassification improvement. We found that in primary cultured human glomerular endothelial cells, TGFβ treatment induced fibrosis, and the protein expression levels of collagen I, collagen IV, fibronectin, and αSMA were decreased after administration of an agonistic cMet antibody. In conclusion, elevated levels of urinary cMet at the time of initial diagnosis could predict renal outcomes in patients with DN.Yong Chul KimJung Nam AnJin Hyuk KimYoung-Wook ChoiSohee OhSang Ho KwonMi-Young LeeJunghun LeeJae-Gyun JeongChun Soo LimYon Su KimSeung Hee YangJung Pyo LeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yong Chul Kim Jung Nam An Jin Hyuk Kim Young-Wook Choi Sohee Oh Sang Ho Kwon Mi-Young Lee Junghun Lee Jae-Gyun Jeong Chun Soo Lim Yon Su Kim Seung Hee Yang Jung Pyo Lee Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
description	Abstract Hepatocyte growth factor and its receptor cMet activate biological pathways necessary for repair and regeneration following kidney injury. Here, we evaluated the clinical role of urinary cMet as a prognostic biomarker in diabetic nephropathy (DN). A total of 218 patients with DN were enrolled in this study. We examined the association of urine cMet levels and long-term outcomes in patients with DN. The levels of urinary cMet were higher in patients with decreased renal function than in patients with relatively preserved renal function (5.25 ± 9.62 ng/ml versus 1.86 ± 4.77 ng/ml, P = 0.001). A fully adjusted model revealed that a urinary cMet cutoff of 2.9 ng/mL was associated with a hazard ratio for end-stage renal disease of 2.33 (95% confidence interval 1.19–4.57, P = 0.014). The addition of urinary cMet to serum creatinine and proteinuria provided the highest net reclassification improvement. We found that in primary cultured human glomerular endothelial cells, TGFβ treatment induced fibrosis, and the protein expression levels of collagen I, collagen IV, fibronectin, and αSMA were decreased after administration of an agonistic cMet antibody. In conclusion, elevated levels of urinary cMet at the time of initial diagnosis could predict renal outcomes in patients with DN.
format	article
author	Yong Chul Kim Jung Nam An Jin Hyuk Kim Young-Wook Choi Sohee Oh Sang Ho Kwon Mi-Young Lee Junghun Lee Jae-Gyun Jeong Chun Soo Lim Yon Su Kim Seung Hee Yang Jung Pyo Lee
author_facet	Yong Chul Kim Jung Nam An Jin Hyuk Kim Young-Wook Choi Sohee Oh Sang Ho Kwon Mi-Young Lee Junghun Lee Jae-Gyun Jeong Chun Soo Lim Yon Su Kim Seung Hee Yang Jung Pyo Lee
author_sort	Yong Chul Kim
title	Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
title_short	Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
title_full	Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
title_fullStr	Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
title_full_unstemmed	Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
title_sort	soluble cmet levels in urine are a significant prognostic biomarker for diabetic nephropathy
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/00399e8fbf4e4a6fbd44b1b1795bdc1f
work_keys_str_mv	AT yongchulkim solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT jungnaman solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT jinhyukkim solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT youngwookchoi solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT soheeoh solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT sanghokwon solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT miyounglee solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT junghunlee solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT jaegyunjeong solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT chunsoolim solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT yonsukim solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT seungheeyang solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy AT jungpyolee solublecmetlevelsinurineareasignificantprognosticbiomarkerfordiabeticnephropathy
_version_	1718387978672275456

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy

Ejemplares similares